TILT-123 is under clinical development by TILT Biotherapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TILT-123’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TILT-123 overview
TILT-123 is under development for the treatment of metastatic melanoma, ovarian cancer, peritoneal cancer, sarcomas, non-small cell lung cancer, lung cancer and fallopian tube cancer, SCCHN and refractory solid tumors. TILT-123 is a 5/3 chimeric serotype oncolytic adenovirus expressing human TNFalpha and human IL-2. TILT-123 is administered through intra-tumoral or intravenous route. The drug candidate is being developed as chimeric antigen receptor T cells for solid tumor.
It was also under development for the treatment of solid tumor.
TILT Biotherapeutics overview
TILT Biotherapeutics is a clinical-stage biotechnology company that develops cancer immunotherapies. The company offers product pipeline such as TILT-123, TILT-234, TILT 452 and TILT 321. Its pipeline treats melanoma, ovarian cancer, lung cancer, head and neck cancer, pancreas cancer and solid tumors. TILT Biotherapeutics also include TILT technology based on oncolytic viral therapies for enabling tumor T-cell therapy by tumor-infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR) and checkpoint-inhibiting antibody therapy for solid tumor. The company has collaborations with Merck-Pfizer Alliance, MSD International GmbH, University of Helsinki and University of Pennsylvania. TILT Biotherapeutics is headquartered in Helsinki, Finland.
For a complete picture of TILT-123’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
